Fabry International Prognostic Index: a predictive severity score for Anderson-Fabry disease
- 7 February 2012
- journal article
- Published by BMJ in Journal of Medical Genetics
- Vol. 49 (3) , 212-220
Abstract
Background Anderson-Fabry disease (AFD) is a disorder of glycosphingolipid metabolism resulting from deficiency of α-galactosidase A and accumulation of globotriaosylceramide. Presentation is heterogeneous and, despite guidelines for initiation of therapy, there is no basis for defining subgroups that will progress more rapidly, whether treated or not. The authors of this study used clinical and pathological data recorded on 1483 patients in the Fabry Outcome Survey, a large international registry, to develop a prognostic severity score. Methods Parameters relevant to disease progression or outcome were initially selected, using variables that are readily available in clinical practice. Individual end points for renal, cardiac, neurological disease, and death were selected, and a composite end point developed. Potential prognostic variables were correlated with each end point, before multivariate analysis. Variables retaining significance were then used to construct organ specific and composite prognostic scores. Kaplan–Meier (KM) analysis, according to score, was performed for each end point. Results Analysis demonstrated that it is possible to differentiate groups of patients with different outcome probabilities. Cardiac, renal and neurological end points could each be categorised into three separate groups. The 80% event-free survival for these groups differed by approximately 10 years. The overall composite score, the Fabry International Prognostic Index (FIPI), distinguished two distinct groups where the 50% event-free survival differed by 10 years. Conclusions A prognostic scoring system for AFD has been developed and retrospective validation performed. The FIPI should prove to be a valuable tool in the counselling and management of AFD patients, and in comparative analyses of outcome using different therapies.Keywords
This publication has 21 references indexed in Scilit:
- A validated disease severity scoring system for Fabry diseaseMolecular Genetics and Metabolism, 2010
- High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*The American Journal of Human Genetics, 2006
- The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry diseaseActa Paediatrica, 2006
- Patients with Fabry disease on dialysis in the United StatesKidney International, 2002
- Anderson–Fabry disease: Clinical manifestations of disease in female heterozygotesJournal of Inherited Metabolic Disease, 2001
- Enzyme Replacement Therapy in Fabry DiseaseJAMA, 2001
- Natural history of Fabry disease in affected males and obligate carrier femalesJournal of Inherited Metabolic Disease, 2001
- A Phase 1/2 Clinical Trial of Enzyme Replacement in Fabry Disease: Pharmacokinetic, Substrate Clearance, and Safety StudiesThe American Journal of Human Genetics, 2001
- Prevalence of Lysosomal Storage DisordersJAMA, 1999
- Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findingsThe American Journal of Cardiology, 1986